Skip Nav Destination
Issues
1 September 2022
-
Cover Image
Cover Image
Scheme of the different signaling pathways where YES1 phosphorylation participates in cancer cells to promote proliferation, migration, invasion, and metastasis. Read the full article by Garmendia and colleagues on page 1371. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Small Molecule Therapeutics
Large Molecule Therapeutics
Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody–Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer
Stephen J. Gregson; Kathryn Pugh; Neki Patel; Shameen Afif-Rider; Balakumar Vijayakrishnan; Kathleen Santos; Jitka Riedl; Ian Hutchinson; Gyoung-Dong Kang; K. Phin Chooi; Rhiannon Beard; Lauren Adams; Conor S. Barry; Kathryn Ball; Luke A. Masterson; Mary McFarlane; John A. Hartley; Philip W. Howard
Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade
Andrea T. Hooper; Kimberly Marquette; Chao-Pei Betty Chang; Jonathon Golas; Sadhana Jain; My-Hanh Lam; Magali Guffroy; Mauricio Leal; Hadi Falahatpisheh; Divya Mathur; Ting Chen; Kerry Kelleher; Kiran Khandke; Elwira Muszynska; Frank Loganzo; Edward Rosfjord; Judy Lucas; Zhengyan Kan; Chakrapani Subramanyam; Christopher O'Donnell; Dario Neri; Hans-Peter Gerber; Chad May; Puja Sapra
Targeting Drug Resistance
Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma
Florencia Cayrol; Maria V. Revuelta; Mercedes Debernardi; Alejandra Paulazo; Jude M. Phillip; Nahuel Zamponi; Helena Sterle; María C. Díaz Flaqué; Cynthia Magro; Rossella Marullo; Erin Mulvey; Jia Ruan; Graciela A. Cremaschi; Leandro Cerchietti
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.